Value of Extended Adjuvant AI Therapy Is Still Unclear

At SABCS 2016, investigators reported 3 new studies on extended adjuvant aromatase inhibitors (AIs)—a large American trial (NRG Oncology/NSABP B-42) and 2 relatively small Dutch ones (IDEAL and DATA).^1-3 None of these trials showed that extending AIs was beneficial with respect to extending disease-free survival (DFS) or overall survival (OS), but the NSABP B-42 trial showed a statistically significant reduction in the